Global AI in Clinical Trials Market to Show Tremendous Growth at a CAGR of ~12% by 2032
By GlobeNewswire Published on May 7, 2025, 22:00 IST
New York, USA, May 07, 2025 (GLOBE NEWSWIRE) — Global AI in Clinical Trials Market to Show Tremendous Growth at a CAGR of ~12% by 2032 | DelveInsight
The demand for AI in clinical trials is experiencing strong growth, primarily fueled by the rising global prevalence of chronic illnesses like diabetes, cardiovascular diseases, respiratory conditions, and cancer. This growth is further bolstered by increasing investments and funding dedicated to enhancing drug discovery and development. Additionally, the expanding trend of strategic alliances and partnerships among pharmaceutical, biotechnology, and medical device firms is significantly contributing to the accelerated adoption of AI-driven clinical trial technologies.
DelveInsight's AI in Clinical Trials Market Insights report provides the current and forecast market analysis, individual leading AI in clinical trials companies' market shares, challenges, AI in clinical trials market drivers, barriers, trends, and key market AI in clinical trials companies in the market.
Key Takeaways from the AI in Clinical Trials Market Report As per DelveInsight estimates, North America is anticipated to dominate the global AI in clinical trials market during the forecast period.
In the product segment of the AI in clinical trials market, the software category had a significant revenue share in 2024.
Notable AI in clinical trials companies such as TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Unlearn.ai, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, and several others are currently operating in the AI in clinical trials market.
and several others are currently operating in the AI in clinical trials market. In March 2025, Suvoda launched Sofia, an AI-powered assistant designed to streamline clinical trial management. Built to support study teams, Sofia simplifies access to and review of critical trial information by delivering intelligent, real-time insights. This innovation enhances operational efficiency, reduces manual workload, and empowers teams to make faster, data-driven decisions throughout the trial lifecycle.
launched Sofia, an AI-powered assistant designed to streamline clinical trial management. Built to support study teams, Sofia simplifies access to and review of critical trial information by delivering intelligent, real-time insights. This innovation enhances operational efficiency, reduces manual workload, and empowers teams to make faster, data-driven decisions throughout the trial lifecycle. In December 2024, ConcertAI and NeoGenomics announced the launch of CTO-H, a next-generation AI software solution for research analytics, clinical trial design, and operational optimization. CTO-H delivers an unparalleled research data platform, offering unmatched scale, longitudinal patient insights, and deep biomarker data, enabling more precise, efficient, and data-driven clinical development strategies.
announced the launch of CTO-H, a next-generation AI software solution for research analytics, clinical trial design, and operational optimization. CTO-H delivers an unparalleled research data platform, offering unmatched scale, longitudinal patient insights, and deep biomarker data, enabling more precise, efficient, and data-driven clinical development strategies. In June 2024, Lokavant launched Spectrum™, the first AI-driven clinical trial feasibility solution designed to optimize trial performance across the entire clinical development value chain. Spectrum empowers study teams to predict, manage, and optimize trial timelines and costs in real-time.
To read more about the latest highlights related to the AI in clinical trials market, get a snapshot of the key highlights entailed in the Global AI in Clinical Trials Market Report
AI in Clinical Trials Overview
Artificial intelligence (AI) is revolutionizing clinical trials by enhancing efficiency, accuracy, and patient outcomes across the entire trial lifecycle. AI-powered tools enable faster patient recruitment by analyzing electronic health records and identifying eligible candidates based on complex inclusion and exclusion criteria. This targeted approach reduces trial enrollment time and improves diversity among participants. Additionally, AI can optimize trial design by simulating outcomes using real-world data, allowing researchers to refine protocols and predict potential risks, ultimately leading to more robust and reliable results.
Moreover, AI facilitates real-time monitoring and data analysis during trials, enabling early detection of adverse events and anomalies. Machine learning algorithms can process vast amounts of data from wearable devices, lab results, and patient-reported outcomes to identify patterns that might be overlooked by traditional methods. This enhances decision-making and allows for adaptive trial designs, where protocols can be modified in response to interim findings. As regulatory bodies grow more comfortable with AI-driven methodologies, the integration of AI in clinical trials holds the promise of accelerating drug development while ensuring safety and efficacy.
AI in Clinical Trials Market Insights
North America held the largest share of the AI in clinical trials market in 2024. This leading position is driven by several key factors, including the increasing burden of chronic diseases, substantial R&D investments, and a growing volume of clinical trials in the region. The market is also benefiting from the rise in research collaborations and strategic partnerships among pharmaceutical and medical device companies, alongside the continuous development of sophisticated AI technologies.
Major players in the North American market are making significant R&D investments to develop cutting-edge AI tools aimed at streamlining clinical trials. For instance, in October 2022, Phesi introduced its AI-driven Trial Accelerator platform, which enhances clinical trial planning through real-time scenario analysis. Utilizing the world's most comprehensive clinical trial database, this SaaS platform helps optimize patient recruitment, endpoint determination, country selection, and site allocation—boosting trial efficiency and outcomes.
Likewise, in October 2023, H1 launched GenosAI, a generative AI feature integrated into its Trial Landscape platform. GenosAI is designed to improve clinical trial decision-making by enabling pharmaceutical companies to analyze complex data, simplify trial-related queries, and expedite the selection of sites and principal investigators, thereby facilitating quicker and more strategic trial initiations.
As a result, these factors are expected to drive substantial growth in the North American AI in clinical trials market throughout the 2025–2032 forecast period.
To know more about why North America is leading the market growth in the AI in clinical trials market, get a snapshot of the AI in Clinical Trials Market Outlook
AI in Clinical Trials Market Dynamics
The AI in clinical trials market is experiencing significant growth, driven by advancements in artificial intelligence, machine learning, and data analytics. AI technologies are being increasingly adopted to streamline clinical trial processes, such as patient recruitment, data collection, and monitoring. AI-powered tools help researchers identify suitable candidates faster, reducing the time and costs associated with recruitment. Additionally, AI aids in personalized treatment regimens by analyzing large datasets to identify optimal patient profiles and predict outcomes more accurately.
One of the major factors fueling the market's growth is the need for improving efficiency in clinical trials. AI facilitates real-time monitoring of patient health, enabling researchers to detect potential issues early and make data-driven decisions. By automating time-consuming tasks, AI reduces human error, improves trial design, and accelerates the pace of development for new therapies. This increased efficiency is especially critical as the pharmaceutical industry faces growing pressure to bring drugs to market quickly due to competitive pressures and a rising demand for novel treatments.
Another key driver in the AI in clinical trials market is the increasing complexity of modern drug development. With more targeted therapies, such as immunotherapies and gene therapies, clinical trials require sophisticated designs to accommodate diverse patient populations and intricate treatment regimens. AI technologies, including predictive analytics and natural language processing, help streamline this complexity by analyzing vast datasets to uncover meaningful insights. This supports the creation of more robust trial designs and accelerates decision-making processes, ultimately reducing costs.
Despite its advantages, the adoption of AI in clinical trials faces challenges, such as concerns around data privacy, regulatory compliance, and the need for skilled personnel. Healthcare data is highly sensitive, and regulatory bodies are still adapting to ensure AI tools meet the necessary standards for clinical use. Furthermore, while AI can greatly assist in data analysis, the technology still requires human oversight to interpret results and ensure that ethical guidelines are followed. Addressing these challenges will be crucial for widespread AI adoption and for realizing its full potential in clinical trials.
Looking ahead, the AI in clinical trials market is expected to expand further with the integration of more advanced AI capabilities, including deep learning and real-time data integration from wearables and remote monitoring devices. As healthcare systems continue to digitize and AI technologies evolve, their use in clinical trials will likely become more ubiquitous, making trials faster, cheaper, and more effective. The market is poised for continued growth, with AI playing a pivotal role in shaping the future of clinical research.
Get a sneak peek at the AI in clinical trials market dynamics @ AI in Clinical Trials Market Dynamics Analysis Report Metrics Details Coverage Global Study Period 2022–2032 AI in Clinical Trials Market CAGR ~12% AI in Clinical Trials Market Size by 2032 USD 3.3 Billion Key AI in Clinical Trials Companies TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Unlearn.ai, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, among others
AI in Clinical Trials Market Assessment AI in Clinical Trials Market Segmentation AI in Clinical Trials Market Segmentation By Product: Software and Services AI in Clinical Trials Market Segmentation By Technology: Machine Learning (ML), Natural Language Processing (NLP), and Others AI in Clinical Trials Market Segmentation By Application: Clinical Trial Design & Optimization, Patient Identification & Recruitment, Site Identification & Trial Monitoring, and Others AI in Clinical Trials Market Segmentation By Therapeutic Area: Oncology, Cardiology, Neurology, Infectious Disease, Immunology, and Others AI in Clinical Trials Market Segmentation By End-User: Pharmaceutical & Biotechnology Companies and Medical Device Companies AI in Clinical Trials Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World
Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View
Which MedTech key players in the AI in clinical trials market are set to emerge as the trendsetter explore @ AI in Clinical Trials Companies
Table of Contents 1 AI in Clinical Trials Market Report Introduction 2 AI in Clinical Trials Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 AI in Clinical Trials Market Key Factors Analysis 6 AI in Clinical Trials Market Porter's Five Forces Analysis 7 AI in Clinical Trials Market Layout 8 AI in Clinical Trials Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us
Interested in knowing the AI in clinical trials market by 2032? Click to get a snapshot of the AI in Clinical Trials Market Trends
Related Reports
Artificial Intelligence in Drug Commercialization Market
Artificial Intelligence in Drug Commercialization Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in drug commercialization companies, including EVERSANA, Lyfegen, Syneos Health, McKinsey & Company, ICON plc., Clarivate., Thermo Fisher Scientific Inc., Viseven, ZS Associates, Cloud Pharmaceuticals Inc., among others.
Artificial Intelligence in Precision Medicine Market
Artificial Intelligence in Precision Medicine Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in precision medicine companies, including TEMPUS, GE HealthCare, Qure.ai, Envisionit Deep AI (Pty) Ltd., Avicenna.AI, Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., among others.
Artificial Intelligence In Drug Discovery Market
Artificial Intelligence In Drug Discovery Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in drug discovery companies, including IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Atomwise Inc, Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), Insilico Medicine, BenevolentAI, Exscientia, Cyclia, Valo Health, Owkin Inc, Verge Genomics, BioSymetrics, among others.
Artificial Intelligence in Medical Imaging Market
Artificial Intelligence in Medical Imaging Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in medical imaging companies, including Microsoft, Siemens Healthineers, GE Healthcare, NVIDIA Corporation, Philips Healthcare, Arterys, Butterfly Network, Enlitic, HeartFlow, Digital Diagnostics, among others.
Artificial Intelligence in Life Sciences Market
Artificial Intelligence in Life Sciences Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in life sciences companies, including IBM Corporation, Atomwise, Inc., Nuance Communications, Inc., NuMedii, Inc., AiCure LLC, APIXIO, Inc., Insilico Medicine, Inc., Enlitic, Inc., Sensely, Inc., Zebra Medical Vision, among others.
DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Golfing Queen Gathers Sports Legends for the All Sports Reunion: Legends & Executives Golf Invitational at Pebble Beach
Pebble Beach, CA, June 12, 2025 (GLOBE NEWSWIRE) -- , led by founder and CEO Sheila Washington, is proud to announce the All Sports Reunion: Legends & Executives Golf Invitational, set for Oct. 12–13, 2025, at The Hay, the iconic 9-hole golf course at Pebble Beach Sports Reunion Golf Invitational October 12&13 2025This exclusive two-day experience will unite professional sports legends—from the major sports leagues and beyond—with top corporate executives for a premier weekend of golf, networking, and philanthropy. The event kicks off with a VIP Welcome Jazz Reception at the Hyatt Regency Monterey Hotel, setting the stage with a stylish, relaxed atmosphere for meaningful connections. The following day, participants will tee off at The Hay, the acclaimed 9-hole course at Pebble Beach, followed by an elegant Awards Dinner. Players will compete for exciting hole-in-one cash prizes and a coveted spot in the $100,000 shoot-out on Hole #1 at the legendary Pebble Beach Golf Links. More than a golf event, the Invitational is a celebration of purpose-driven impact. Proceeds from the event help support youth development, educational initiatives, health advocacy, and community programs that empower families, children, and underserved communities. Through this Invitational, we bring together sports, philanthropy, and leadership to make a lasting difference beyond the green.'This event is more than just golf — it's about a reunion of sports legends and executives creating memories, making an impact, and celebrating the love of the game,' said Washington. 'We're gathering those who care about giving back, and that's what makes this so special.'Sponsorship details, registration, and a list of confirmed athletes are available at About Golfing Queen Golfing Queen aims to inspire and empower women, kids & corporations to embrace the sport of golf through engaging clinics, social events, and educational programs. We create a supportive environment where women of all ages and skill levels can connect, improve their game, and foster lifelong relationships—all while promoting healthy living and community involvement. Golfing Queen's signature golf event is the ALL SPORTS REUNION Legends & Executive Invitational in Pebble Beach, CA, October 12 & 13, 2025. Press inquiries Golfing Queen Alex Nicole Garza alex@ 833-388-GOLF (4653) A video accompanying this announcement is available at
Yahoo
25 minutes ago
- Yahoo
Personalized, Efficient, and On-Brand: The Human Bean's Journey into AI
Harnessing the Power of AI with a Human Touch Medford, OR, June 12, 2025 (GLOBE NEWSWIRE) -- While artificial intelligence (AI) is the buzzword dominating conversations in every industry, The Human Bean is turning talk into action—leveraging AI not just for efficiency, but to elevate the customer experience, support franchisee partners, and infuse brand personality into every touchpoint. For The Human Bean, AI isn't about replacing people; it's about enhancing their impact. From review responses to creative design, the brand is harnessing the power of AI to support its franchise network and reinforce its values of experience, integrity, community and quality. 'Our approach is grounded in practical results,' said Janie Page, Chief Marketing Officer at The Human Bean. 'One of our first major steps was adopting SOCi Genius Reviews. This tool allows us to respond to reviews with customized, brand-aligned messages that reflect our tone—mentioning the customer's name, drinks by name, and speaking directly to the customer's experience. It saves time while feeling more personal than ever.' Franchisees have reported reduced review response time and more meaningful engagement, further validating the impact of AI when used thoughtfully. Other teams have found value in Adobe's generative fill and text-to-image tools, which cut design time from hours to minutes, making it easier to create on-brand visuals for promotions and social media. AI-generated mockups provide inspiration and efficiency—two key ingredients in a fast-moving marketing environment. Franchise-wide adoption has been strategic. 'We piloted tools with clear value and communicated them as assistants—not replacements,' explained Page. 'For example, with SOCi, franchise partners still approve all responses. It's not about removing the human; it's about giving them superpowers versus finding a template that matches the need.' 'At SOCi, we believe AI should act as an extension of your brand's voice, not a replacement for it,' say Monica Ho, Chief Marketing Office at SOCi. 'The Human Bean is a perfect example of how to use AI to make every customer feel seen and valued—turning a simple review into a personal, brand-aligned conversation. Our consumer research consistently shows that personalization drives loyalty, and when brands use AI to enhance speed and relevance without losing their human touch, they build stronger connections and drive real business outcomes."The company's advice to others in the franchise space? 'Start small, stay flexible, and stay human. AI is only as strong as the people guiding it,' said Page. 'If you treat AI as a creative collaborator, it can help you deliver more thoughtful, personalized content—without losing your brand voice.' With plans to continue expanding AI usage across marketing and operations, The Human Bean is proving that even in a digital age, the human touch still leads the way. About The Human Bean With a passion for creating happy 'Human Beans', the company's drive-thrus around the U.S. have established a reputation for friendly baristas and high-quality coffee, teas, smoothies, granitas, Bright® Energy and good eats. The Human Bean opened its first drive-thru espresso stand in Ashland, Oregon in 1998, and currently supports over 260 locations open or under development in 23 states. Learn more at Attachment Harnessing the Power of AI with a Human Touch CONTACT: Kathryn Braet The Human Bean 541-608-0564 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Intelligent Airways Transportation Industry Analysis Report 2025-2034: Digital Twins and Predictive Models Revolutionizing Operations
The Intelligent Airways Transportation Market is valued at USD 18.4 billion in 2025 and is projected to reach USD 41.9 billion by 2034 with a 9.6% CAGR. Key trends include AI-driven operations, digital twins, and biometric security, driven by rising air traffic and sustainability demands. Chief markets are North America, Europe, and Asia-Pacific. Intelligent Airways Transportation Market Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Intelligent Airways Transportation Market 2025-2034" has been added to offering. The Intelligent Airways Transportation Market is projected to reach a valuation of USD 18.4 billion by 2025, with an anticipated CAGR of 9.6% leading to USD 41.9 billion by 2034. This market is driving the advancement of smart aviation infrastructure, leveraging data-driven systems, automation, and AI to refine airline operations, passenger experience, and air traffic control. With global air travel on the rise, airport efficiency demands, and a growing emphasis on sustainability, the integration of intelligent systems in air transportation has become vital. Airlines and airport authorities are investing in AI-powered predictive maintenance, automated check-in systems, smart baggage handling, and biometric identification to facilitate seamless passenger journeys. These technological advancements significantly reduce delays, enhance safety, and cut operational costs. The market's development is influenced by the intersection of digital transformation strategies and the need to manage increasing air traffic congestion in major hubs. The ongoing convergence of cloud computing, IoT, machine learning, and 5G connectivity sets the pace for modernization in air transport. As of 2024, a spectrum of stakeholders, from aviation IT companies to AI startups, is collaborating to create scalable and interoperable solutions. The implementation of these technologies is no longer limited to international airports but is expanding to regional facilities, signaling a broadened market scope. Notably, in 2024, key airports like Changi, Heathrow, and Atlanta Hartsfield have adopted AI-driven decision-making across operations, employing digital twins and machine learning to enhance resource management dynamically. In response to increasing post-pandemic travel demands, the aviation industry accelerated digital upgrades, particularly in areas boosting passenger facilitation and operational resilience. Biometric security systems have become prevalent, backed by the U.S. TSA and European regulators, promoting facial recognition for boarding and security checks. Real-time analytics equipped airports to counteract disruptions caused by weather or equipment failures proactively. Green aviation initiatives have aligned with intelligent transport systems, focusing on monitoring carbon footprints and optimizing energy consumption. Platforms such as SITA Flex and Amadeus Airport Management have been updated to accommodate agile deployments across various airports. Cybersecurity has become a prominent concern, with a focus on implementing zero-trust architectures to protect the interconnected aviation networks. The developments of 2024 emphasize a pressing need for digitizing aviation infrastructure while securing adaptability and regulatory compliance amidst global uncertainty. Looking toward 2025 and beyond, the market is likely to shift toward hyper-personalization and cognitive automation. Airlines will not only use AI for operations but also to offer bespoke in-flight services and loyalty programs, catering to individual passenger preferences. Future AI-powered control towers are set to revolutionize air traffic management, particularly in congested airspace. The integration of autonomous vehicles, including luggage carriers and airside logistics robots, will advance, propelled by public and private investment. This technological evolution will be supported by global aviation authorities working towards establishing unified digital governance frameworks that enable interoperability and data sharing across international terminals. The advent of eVTOL (electric vertical take-off and landing) aircraft will necessitate synchronized airspace and urban mobility management systems. Looking ahead, the potential inclusion of quantum computing and neuromorphic chips in R&D could further revolutionize high-volume decision-making systems. As geopolitical shifts and environmental regulations mold aviation priorities, intelligent transport systems will be pivotal in ensuring operational flexibility, sustainability, and customer-focused air travel solutions. Key Insights Intelligent Airways Transportation Market Airports are increasingly adopting digital twin technology to optimize operations and improve efficiency. Biometric and facial recognition technologies enhance security and streamline passenger journeys. AI and ML are pivotal in demand forecasting and resource allocation, enhancing operational efficiency. The trend toward multi-airport system coordination is on the rise, optimizing air traffic management. Sustainability is becoming central, with smart platforms monitoring energy use and supporting environmental goals. Cloud infrastructure advancements facilitate rapid deployment of smart transport systems. Enhanced passenger expectations for tech-driven experiences drive investment in intelligent automation. Integration challenges of legacy and modern systems remain, impacting timelines and costs. Cybersecurity investment is essential to combat increasing threats to aviation networks. Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $18.4 Billion Forecasted Market Value (USD) by 2034 $41.9 Billion Compound Annual Growth Rate 9.5% Regions Covered Global Companies Featured Amadeus IT Holding S.A. Cisco Systems Inc. Indra Sistemas S.A. International Business Machines Corporation Nippon Electric Company Limited Siemens AG Rockwell Collins Inc. Societe International de Telecommunications Aeronautiques Unisys Corporation Honeywell International Inc. Zhongxing New Telecommunications Equipment Co. Ltd. Microsoft Corporation Oracle Corporation Thales Group Inc. Raytheon Technologies Corporation Saab AB L3Harris Technologies Inc. Frequentis AG ADB SAFEGATE Northrop Grumman Corporation Saipher ATC Lockheed Martin Corporation Airbus SE Adacel Technologies Limited SkySoft-ATM Threod Systems Intelcan Technosystems Inc. Leonardo S.p.A. ALTYS Technologies Skygyuid For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Intelligent Airways Transportation Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
